Dr. Irena Melnikova joined the TVM Capital Life Science team in 2008. She is a Senior Associate in the Boston office and assists in the management of TVM Capital’s investments and due diligence.
Prior to TVM Capital, she launched and produced “Future in Focus,” a series of syndicated reports for Leerink Swann and was a member of the biopharma investment banking team where she supported due diligence and opportunity assessment activities that resulted in public and private financings as well as M&A transactions.
Prior to Leerink Swann, Dr. Melnikova was a Research Manager at Life Science Insights, a subsidiary of IDC, the leading technology market research company.
As a project leader at TransForm Pharmaceuticals (acquired by Johnson & Johnson), she was responsible for running several programs including Engineered Tissue Constructs and Amyloidoses.
She holds a Ph. D. in Molecular Medicine/Molecular Biology from the University of Texas and an MS with Honors in Chemical Engineering from Russian University of Chemical Technology. Dr. Melnikova is a regular contributor to the “Analyst Couch” section of Nature Reviews in Drug Discovery magazine. She is the co-inventor on a filed patent for methods for identifying conditions affecting a cell state.
To read her most recent article in Nature Review, → please click here.
